These obvious valuable effects of RUT on CPZ-induced demyelination, which might be mediated by inhibition of NF-κB and Keap1–Nrf2 protein–protein interaction, in addition to its possibility to affect HLA gene, suggest that RUT could emerge as a candidate for MS treatment. The gene discussed is NFE2L2; the disease is myeloid sarcoma.